- Home
- OGI vs CGEN Comparison
OGI vs CGEN Comparison
Compare OGI & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- CGEN
- Stock Information
- Founded
- OGI 2013
- CGEN 1993
- Country
- OGI Canada
- CGEN Israel
- Employees
- OGI N/A
- CGEN N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OGI Health Care
- CGEN Health Care
- Exchange
- OGI Nasdaq
- CGEN Nasdaq
- Market Cap
- OGI 135.1M
- CGEN 135.6M
- IPO Year
- OGI N/A
- CGEN 2000
- Fundamental
- Price
- OGI $1.07
- CGEN $1.47
- Analyst Decision
- OGI
- CGEN Strong Buy
- Analyst Count
- OGI 0
- CGEN 1
- Target Price
- OGI N/A
- CGEN $4.00
- AVG Volume (30 Days)
- OGI 484.7K
- CGEN 268.4K
- Earning Date
- OGI 05-13-2025
- CGEN 05-19-2025
- Dividend Yield
- OGI N/A
- CGEN N/A
- EPS Growth
- OGI N/A
- CGEN N/A
- EPS
- OGI N/A
- CGEN N/A
- Revenue
- OGI $115,451,336.00
- CGEN $27,864,000.00
- Revenue This Year
- OGI $50.11
- CGEN $11.81
- Revenue Next Year
- OGI $16.16
- CGEN $28.37
- P/E Ratio
- OGI N/A
- CGEN N/A
- Revenue Growth
- OGI N/A
- CGEN N/A
- 52 Week Low
- OGI $0.85
- CGEN $1.13
- 52 Week High
- OGI $2.17
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- OGI 52.89
- CGEN 49.50
- Support Level
- OGI $1.02
- CGEN $1.13
- Resistance Level
- OGI $1.11
- CGEN $1.35
- Average True Range (ATR)
- OGI 0.07
- CGEN 0.11
- MACD
- OGI 0.02
- CGEN 0.03
- Stochastic Oscillator
- OGI 84.62
- CGEN 85.00
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.